All Type of News
Insurance pricing on new drugs specially privileged
The foreign multinational drug companies and local drug industries shared with common goals for the future insurance reimbursement price of new drugs to get some privileges in process of the government price determina...
Equivalent drug efficacy test to differentiate by dosage forms.
The civic group strongly demanded the equivalent drug efficacy test for all existing drugs in conjunction with the implementation of the medical and pharmacy separation plan. However, this issue was rejected in view o...
Strategic tie-up between Yuhan and Schering Plough
Yuhan and Schering Plough signed an agreement at the conference room of Yuhan on July 19 for a strategic partnership. According to the Agreement, Yuhan will distribute Schering's products, Icepacin (a broad spe...
Bioequivalency test for 105 products completed.
The KFDA reported that as of the end of July this year 105 drugs have completed the bioequivalency test since implementation of its provision in 1998, which was 90 items increases during the past 9 months from 85 pro...
Enforcement provisions of medical and pharmacy separation system finally drafted.
The MOHW took a meeting of the Health Policy Subcommittee, the Implementation Commission for Medical and Pharmacy Separation System at the conference room of Korea Health and Industry Promotion Board on July 16 and de...
KFDA approved product licence transfer to Green Cross affiliates
The transfer of individual product licence permitted for the company M&A and split made it possible that the local pharmaceutical industry could enhance international competitiveness by a massive restructuring for ind...
Hospital margins still requested for imported drugs.
The insurance reimbursement scheme for imported drugs was scheduled to launch from coming August according to the government notification, but the drug industry encountered difficult situations on account of over 10% ...
KRPIA denounced government insurance pricing plan on imported drugs.
The KRPIA denounced the government claims for the imported drug insurance reimbursement price to be equally set up with the domestic drugs as "the equal treatment by Korean style" without consideration of internationa...
Dongwha's DW166HC likely to be No. 2 new drugs in Korea.
SK pharmaceutical obtained the manufacturing licence of a platinum complex preparation as a new drug with passing through the clinical phase II studies only, which was exceptional for an anticancer drug while provisio...
Sunpla expected yearly to yeild 10 billion won of sales
As reported earlier SK Chemical and SK Pharmaceutical has developed an anti-cancer drug, a platinum complex, under the brand of Sunpla by about 8.1 billion won of investment during the past 10 years, which becomes the...
